

Special Issue

Immunogenic Cell Death and Associated Antitumor Immunity

Message from the Guest Editor

Roughly 20 years ago, studies by Zitvogel, Kroemer, and their colleagues showed that some commonly used cytotoxic cancer drugs were stimulating antitumor immune responses against tumors, which were important in those drugs' treatment efficacy. This generated the concept of "immunogenic cell death" (ICD) and added "death-associated molecular patterns" (DAMPs) as additional immunogenic signals to "pathogen-associated molecular patterns" (PAMPs). How ICD, caused by cytotoxic chemotherapy or other cancer treatments such as radiation or heat, interacts with the immune system is still an important topic of active research. This Special Issue is designed to assemble important work in the area of ICD due to cancer therapy, how it interacts with natural or treatment-generated antitumor immunity, and how that response can be further strengthened to improve outcomes for patients

Guest Editor

Prof. Dr. Steven Fiering

1. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
2. Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA

Deadline for manuscript submissions

closed (15 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/123209

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)